Results 301 to 310 of about 77,026 (328)

Meningococcal conjugate vaccines

Expert Opinion on Biological Therapy, 2005
Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire   +3 more sources

Glycoprotein conjugate vaccines

Vaccine, 1999
The polysaccharide capsule which surrounds bacterial species like Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, is a potent virulence factor. It protects the bacterium from phagocytosis, but capsule specific antibodies plus complement binding to the capsule opsonise the organism for phagocytosis and ...
openaire   +3 more sources

Early immunization with conjugate vaccines

Vaccine, 1998
Conjugate vaccines have been used during the neonatal period or in early infancy in order to test their safety and immunologic behaviour. Adverse events even in neonates and premature babies have been mild and spontaneously resolving. Anticapsular antibody concentrations after first doses of Hib conjugates in early infancy are generally low, but ...
Helena Käyhty, Juhani Eskola
openaire   +3 more sources

[Conjugate vaccines].

Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire   +2 more sources

The promise of conjugate vaccines for Africa

Vaccine, 2007
Capsular polysaccharide (PS) vaccines against Neisseria meningitidis and Streptococcus pneumoniae have proven safe and effective. Moreover, experience with N. meningitidis, Haemophilus influenzae type b (Hib) and S. pneumoniae conjugate vaccines has demonstrated that immunogenicity of PS vaccines can be greatly improved by chemical conjugation to a ...
Marie Paule Kieny, F. Marc LaForce
openaire   +3 more sources

Polysaccharide Conjugate Typhoid Vaccine

New England Journal of Medicine, 2001
There is a growing appreciation of the huge health threat posed by increasingly resistant infectious diseases, especially in tropical areas of the developing world.
Richard L. Guerrant, Margaret Kosek
openaire   +3 more sources

PolysaccharicbConjugate Vaccines

2003
It was recognized early this century that small molecules, called haptens, can be made immunogenic after conjugation to carrier proteins (1), This principle was thereafter applied successfully to improve the rmmunogenicity of (poly)saccharides (2, 3). We now know that the carrier proteins ensure the involvement of T-helper lymphocytes in the activation
Odo de Weers, Peter Hoogerhout, Jan Poolman, Carla C. A. M. Peeters, Michel Beurret, Patrick R. Lagerman, Lukas A. Oomen   +6 more
openaire   +3 more sources

Pneumococcal Conjugate Vaccines

1995
The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire   +3 more sources

The pneumococcal protein conjugate vaccines

The Journal of Pediatrics, 2000
to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
Timothy R. Peters, Kathryn M. Edwards
openaire   +3 more sources

Conjugate vaccines: practice and theory

Springer Seminars in Immunopathology, 1993
Conjugate vaccines have already had a major impact on vaccination of infants against H. influenzae type b. The impact of conjugate vaccines will continue to grow as we apply this technology to other important diseases. The design of these vaccines will become more efficient and rational as we continue to understand the various facets and immunological ...
openaire   +3 more sources